166 related articles for article (PubMed ID: 38430394)
21. Identification of a TGF-β signaling-related gene signature for prediction of immunotherapy and targeted therapy for lung adenocarcinoma.
Yu Q; Zhao L; Yan XX; Li Y; Chen XY; Hu XH; Bu Q; Lv XP
World J Surg Oncol; 2022 Jun; 20(1):183. PubMed ID: 35668494
[TBL] [Abstract][Full Text] [Related]
22. Pan-cancer analysis of UBE2T with a focus on prognostic and immunological roles in lung adenocarcinoma.
Cao K; Ling X; Jiang X; Ma J; Zhu J
Respir Res; 2022 Nov; 23(1):306. PubMed ID: 36357897
[TBL] [Abstract][Full Text] [Related]
23. A novel subtype based on driver methylation-transcription in lung adenocarcinoma.
Wang X; Xu Z; Zhao S; Song J; Yu Y; Yang H; Hou Y
J Cancer Res Clin Oncol; 2024 May; 150(5):269. PubMed ID: 38777866
[TBL] [Abstract][Full Text] [Related]
24. Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma.
Huang Z; Li B; Guo Y; Wu L; Kou F; Yang L
Front Immunol; 2021; 12():723172. PubMed ID: 34539658
[TBL] [Abstract][Full Text] [Related]
25. Molecular cluster mining of high-grade serous ovarian cancer via multi-omics data analysis aids precise medicine.
Cai D; Liu T; Fang J; Liu Y
J Cancer Res Clin Oncol; 2023 Sep; 149(11):9151-9165. PubMed ID: 37178426
[TBL] [Abstract][Full Text] [Related]
26. Molecular subtypes of lung adenocarcinoma patients for prognosis and therapeutic response prediction with machine learning on 13 programmed cell death patterns.
Wei Q; Jiang X; Miao X; Zhang Y; Chen F; Zhang P
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11351-11368. PubMed ID: 37378675
[TBL] [Abstract][Full Text] [Related]
27. Gene signature based on B cell predicts clinical outcome of radiotherapy and immunotherapy for patients with lung adenocarcinoma.
Han L; Shi H; Luo Y; Sun W; Li S; Zhang N; Jiang X; Gong Y; Xie C
Cancer Med; 2020 Dec; 9(24):9581-9594. PubMed ID: 33098370
[TBL] [Abstract][Full Text] [Related]
28. High Expression of DLGAP5 Indicates Poor Prognosis and Immunotherapy in Lung Adenocarcinoma and Promotes Proliferation through Regulation of the Cell Cycle.
Tang X; Zhou H; Liu Y
Dis Markers; 2023; 2023():9292536. PubMed ID: 36712920
[TBL] [Abstract][Full Text] [Related]
29. Classification and immunotherapy assessment of lung adenocarcinoma based on coagulation-related genes.
Zhou Y; Fan W; Zhou J; Zhong S; Yang J; Zhong Y; Huang G
Per Med; 2024 Jan; 21(1):29-44. PubMed ID: 38037814
[No Abstract] [Full Text] [Related]
30. Analysis of prognostic model based on immunotherapy related genes in lung adenocarcinoma.
Zhang P; Wang W; Liu L; Li H; Sha X; Wang S; Huang Z; Zhou Y; Shi J
Sci Rep; 2022 Dec; 12(1):22077. PubMed ID: 36543847
[TBL] [Abstract][Full Text] [Related]
31. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
Front Immunol; 2021; 12():693062. PubMed ID: 34497605
[TBL] [Abstract][Full Text] [Related]
32. Identification of a coagulation-related signature correlated with immune infiltration and their prognostic implications in lung adenocarcinoma.
Yang S; Chen S; Zhao Y; Wu T; Wang Y; Li T; Fu L; Ye T; Hu YQ; Chen H
Thorac Cancer; 2023 Nov; 14(33):3295-3308. PubMed ID: 37795779
[TBL] [Abstract][Full Text] [Related]
33. Construction and experimental validation of an acetylation-related gene signature to evaluate the recurrence and immunotherapeutic response in early-stage lung adenocarcinoma.
Wang H; Lu X; Chen J
BMC Med Genomics; 2022 Dec; 15(1):254. PubMed ID: 36503492
[TBL] [Abstract][Full Text] [Related]
34. Single-cell sequencing analysis and transcriptome analysis constructed the macrophage related gene-related signature in lung adenocarcinoma and verified by an independent cohort.
Li R; Tong R; Zhang Z; Deng M; Wang T; Hou G
Genomics; 2022 Nov; 114(6):110520. PubMed ID: 36372305
[TBL] [Abstract][Full Text] [Related]
35. A novel signature predicts prognosis and immunotherapy in lung adenocarcinoma based on cancer-associated fibroblasts.
Ren Q; Zhang P; Lin H; Feng Y; Chi H; Zhang X; Xia Z; Cai H; Yu Y
Front Immunol; 2023; 14():1201573. PubMed ID: 37325647
[TBL] [Abstract][Full Text] [Related]
36. An aging-related signature predicts favorable outcome and immunogenicity in lung adenocarcinoma.
Zhang W; Li Y; Lyu J; Shi F; Kong Y; Sheng C; Wang S; Wang Q
Cancer Sci; 2022 Mar; 113(3):891-903. PubMed ID: 34967077
[TBL] [Abstract][Full Text] [Related]
37. Significance of CD80 as a Prognostic and Immunotherapeutic Biomarker in Lung Adenocarcinoma.
Feng W; He Z; Shi L; Zhu Z; Ma H
Biochem Genet; 2023 Oct; 61(5):1937-1966. PubMed ID: 36892747
[TBL] [Abstract][Full Text] [Related]
38. Dysregulated ferroptosis-related genes indicate potential clinical benefits for anti-PD-1/PD-L1 immunotherapy in lung adenocarcinoma.
Zhou M; Zhang X; Li T; Chen Y
J Clin Lab Anal; 2021 Dec; 35(12):e24086. PubMed ID: 34752672
[TBL] [Abstract][Full Text] [Related]
39. Multi-omics consensus portfolio to refine the classification of lung adenocarcinoma with prognostic stratification, tumor microenvironment, and unique sensitivity to first-line therapies.
Zou Y; Cao C; Wang Y; Zhou Y; Yao S; Zhang L; Zheng K; Zhang H; Qin W; Qin K; Xiong H; Yuan X; Fu S; Wang Y; Xiong H
Transl Lung Cancer Res; 2022 Nov; 11(11):2243-2260. PubMed ID: 36519025
[TBL] [Abstract][Full Text] [Related]
40. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
